1-(2,2,2-TRIFLUOROETHYL)PIPERIDIN-4-OL, 95.0%, 250mg

Sample tub with screw closure, 500 ml, 1 Piece

2-[(4R)-4,5-Dihydro-4-phenyl-2-oxazolyl]-6-(diphenylmethyl)pyridine, 97%, 100mg

alpha,alpha',2,3,5,6-Hexachloro-p-xylene>98.0%(GC)5g

(1S,4R,E)-4-((1R,3aS,7aR,E)-4-((E)-2-((3S,5R)-3,5-bis(tert-butyldimethylsilyloxy)-2-methylenecyclohexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)-1-cyclopropylpent-2-en-1-ol, 98%, 10g

1,3-Oxazinane, 95.0%, 250mg

tert-Butyl (4-bromobutyl)carbamate, 95.0%, 250mg

Methyl 4-bromo-2,3,5,6-tetrafluorobenzoate, 97%, 250mg

S-(Benzo[d]thiazol-2-yl)-N,N-dicyclohexylthiohydroxylamine, 95.0%, 10g

Succinimidyl 4-Azidobutyrate>96.0%(HPLC)100mg

5-METHYL-5H-PYRROLO[2,3-B]PYRAZINE-7-CARBOXYLIC ACID METHYL ESTER, 95.0%, 500mg

E-Plan phase EPLPH 20x/0.40 objective. Working distance 1.85 mm

(R)-Methyl 3-oxocyclopentanecarboxylate, 95.0%, 5g